|
EQS-News: SÜSS MicroTec SE
/ Key word(s): Personnel
Dr. Goetz M. Bendele will not return to the Management Board of SÜSS MicroTec SE | Dr. Bernd Schulte remains in office as Chief Executive Officer (CEO) Garching, Germany, 12/15/2022 – For personal reasons and by mutual agreement with the Supervisory Board of SÜSS MicroTec SE, Dr. Goetz M. Bendele will not be reappointed as a member of the Management Board and Chief Executive Officer of SÜSS MicroTec SE. Dr. Bendele is thus leaving the Company. The Supervisory Board regrets Dr. Bendele's departure and thanks him for his achievements since taking office. The office of Chief Executive Officer (CEO) will continue to be held by Dr. Bernd Schulte, who was delegated to the Management Board from the Supervisory Board in October in order to temporarily replace Dr. Bendele. Dr. Schulte has agreed to take over as Chief Executive Officer until the end of the delegation period, which is not to last more than one year. He will return to the Supervisory Board in October 2023 at the latest. Dr. Schulte served on the Management Board of listed company AIXTRON SE for a total of 19 years until 2021 and is very familiar with SÜSS MicroTec. The Supervisory Board has initiated a process to permanently fill the third Management Board position following the departure of Dr. Bendele next year. Dr. David Dean, Chair of the Supervisory Board of SÜSS MicroTec SE: “We respect Dr. Bendele’s decision not to exercise his right to return to the Management Board of SÜSS MicroTec SE and wish him all the best in his professional and private life. On behalf of the Supervisory Board, I extend my thanks to him for his valuable contributions since joining the Company.” “I would like to extend our thanks to Dr. Schulte for his willingness to continue his full commitment to SÜSS MicroTec SE in his role as Chief Executive Officer in the coming months. It has already become clear in recent weeks that his many years of industry and management experience make him enormously valuable to the Company. We are thus ensuring personnel continuity in this key function during the rest of the transition period. We are moving ahead with filling the third Management Board position quickly while also exercising appropriate due diligence,” Dr. Dean added. Dr. Goetz M. Bendele: "It has been an extraordinary pleasure for me to lead SUSS MicroTec, a globally influential high-tech company with exceptional potential. The company looks back on a positive business development and is today on a sustainable growth path. I would like to thank all my colleagues for their dedication, experience, know-how, and creativity, and wish Dr. Schulte and them all the best and much success in the future." Contact:
About SUSS MicroTec
Legal Disclaimer Contact: SÜSS MicroTec SE Sven Koepsel Investor Relations & Corporate Communications Schleissheimer Strasse 90 85748 Garching, Germany Tel.: +49 89 32007-151 Email: sven.koepsel@suss.com
15.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | SÜSS MicroTec SE |
| Schleissheimer Strasse 90 | |
| 85748 Garching | |
| Germany | |
| Phone: | +49 (0)89 32007-161 |
| Fax: | +49 (0)89 4444 33420 |
| E-mail: | franka.schielke@suss.com |
| Internet: | www.suss.com |
| ISIN: | DE000A1K0235 |
| WKN: | A1K023 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1514675 |
| End of News | EQS News Service |
|
|
1514675 15.12.2022 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
